Jackie Ying pitched her COVID-19 TEPAT 1.0 Kit in the 5th EISA
During her speech in the 5th Exposure of Industries to Scientists’ Achievements Summit (EISA), Jackie Ying, a nanotechnology scientist and the 2015 Mustafa(Pbuh) Prize laureate, talked about COVID-19 TEPAT 1.0 Kit and other products.
MSTF Media reports:
Ying focused on the products developed by Cellbae Pte Ltd, an innovative in-vitro diagnostics company headquartered in Singapore. It spun off from the Agency for Science, Technology and Research (A*STAR) in 2017, launching in-vitro drug toxicity research products worldwide.
The Mustafa
Prize laureate introduced TEPAT 1.0 Multiplex RT-PCR KIT for SARS-CoV-2. This product which is currently on the market provides for high throughput, sensitive and specific detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs.
“TEPAT 1.0 can detect 6 copies of viral RNA per reaction with more than 95 percent confidence,” Ying said. “It has one of the best, if not the best, Limit of Detection in the market right now. It is the only kit in the market that has 100 percent coverage with 100% identity of all SARS-CoV-2 genomes in the world.”
“Clinical validation shows 100% sensitivity, with no cross-reaction with non-SARS-CoV-2 species,” she added.
A noteworthy aspect of this kit is that it detects two genes, Multiplex RdRpP and M viral. An important implication of this feature is that it allows for higher sensitivity and specificity of the kit.
“These genes are exposed to different selective pressure and as such even if the virus mutates, Cellbae’s test should be able to detect these new variants through the detection of at least one of the viral targets,” Ying stated.
In addition, Cellbae has developed TEPAT 2.0 Direct RT-PCR with nasal swab sample, which according to Ying, is currently under review by the Health Sciences Authority of Singapore and expects approval within two weeks.
Ying introduced some additional products developed by Cellabe under the categories of Cellbae Product Pipeline 1, Cellbae Product Pipeline 2, and Cellbae Product Pipeline 3. These include Real Time RT-PCR Assays, Nanoprobe assays, and Seroflow Paper-based Rapid Test Kits.
Ying concluded that Cellbae is developing global reach, looking for distributors, strategic partners and clinical collaborators in the Middle East, South America, Eastern Europe, and North Asia. The company has so far appointed distributors in Nigeria, some countries from Western Europe, and Asia Pacific.
EISA is a platform composed of various commercialization services in the STI Eco-system developed to meet the needs of the Islamic world’s knowledge-based industry and scientific community, enabling technological achievements in products and services to be introduced to new markets, industries, and investors.
The 5th round of EISA focuses on Cutting-edge Healthcare and Medical Achievements. This round is held virtually from November 30th to December 7th, 2020.
